Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4088044 · 1 trial · 1 indication
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4088044 (Part A) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4088044 administered intravenously (IV) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Administered IV |
| LY4088044 (Part B) | EXPERIMENTAL | SAD of LY4088044 administered subcutaneously (SC) |
| Placebo (Part B) | PLACEBO_COMPARATOR | Administered SC |
| LY4088044 (Part C) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4088044 administered IV |
| Placebo (Part C) | PLACEBO_COMPARATOR | Administered IV |
| Name | Type | Description |
|---|---|---|
| LY4088044 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring * Have a body mass index (BMI) within the range 18.5 to 30 kilogram per square meter (kg/m²) Exclusion Criteria: * A...
LY4088044 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development for use in healthy participants. The drug is being studied in a placebo-controlled, double-blind, randomized trial to evaluate its safety and tolerability.
LY4088044 is being studied for use in healthy participants. The ongoing Phase 1 trial is designed to assess the drug's safety and tolerability in this population. It is not yet approved for any medical condition and remains in early-stage clinical development.
LY4088044 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy participants.
LY4088044 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is currently being evaluated in a Phase 1 trial involving healthy participants to assess its safety and tolerability.
LY4088044 is being studied in a Phase 1 clinical trial with the identifier NCT07090785, titled "A Study of LY4088044 in Healthy Participants." The trial is recruiting 104 participants in the United States, New Zealand, and Singapore. It is a randomized, double-blind, placebo-controlled study.
LY4088044 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is evaluating the drug in healthy participants, and it has not yet completed the clinical development process required for regulatory approval.